Research on Diagnostic Markers for Post-Stroke Cognitive Impairment

Area of Science:

• Neurology
• Biochemistry
• Medical Diagnostics

Background:

• Post-stroke cognitive impairment (PSCI) presents a significant global health challenge.
• Accurate diagnosis of PSCI is crucial for timely intervention and management.
• Identifying reliable biomarkers for PSCI is an ongoing area of research.

Purpose of the Study:

• To evaluate the predictive value of beta-amyloid 42 (Aβ42) and hemoglobin (Hb) in diagnosing PSCI.
• To compare the diagnostic performance of Aβ42 and Hb individually and in combination.

Main Methods:

• A cohort of 120 patients was categorized into PSCI, Alzheimer's disease (AD), and post-stroke cognitive normal (PSCN) groups.
• Correlation analysis was performed between Aβ42, Hb, and cognitive scores.
• Logistic regression and ROC curve analysis were employed to assess predictive capabilities.

Main Results:

• Aβ42 and Hb levels were significantly lower in the PSCI group compared to AD and PSCN groups (P < .05).
• Hb was identified as an independent risk factor for PSCI compared to AD and PSCN.
• The combined diagnostic performance of Aβ42 and Hb yielded an AUC of 0.7169, with 80.0% sensitivity and 62.5% specificity.

Conclusions:

• Reduced Aβ42 and Hb levels are associated with PSCI and act as significant risk factors.
• The combined assessment of Aβ42 and Hb demonstrates potential for improved differential diagnosis of PSCI.